Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Tolerability After Intravenous Infusion of UMC119-06 in Subjects With Acute Ischemic Stroke.

NCT04097652 is registered in ClinicalTrials.gov with Meridigen Biotech Co., Ltd. as lead sponsor.

NCT NCT04097652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04097652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Tolerability After Intravenous Infusion of UMC119-06 in Subjects With Acute Ischemic Stroke.
Lead sponsor
Meridigen Biotech Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
December 5, 2019
Completion date
December 31, 2025
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke